Interested in learning more?
Contact Us
ImmunoPrecise’s proprietary Rapid Prime® method identifies positive monoclonal antibodies in as little as 32 days. This method is especially useful for generating anti-idiotypic antibodies and has been extremely useful for producing monoclonal antibodies against conformational epitopes. Other sources of immunogens include conserved or smaller proteins, peptides, and whole cell bacteria.
After the immunization of rodents, we apply our proprietary electrofusion or PEG-fusion to generate hybridomas. The subsequent cloning, using semi-solid media and clone picking to accelerate the process, allows us to identify monoclonal antibody producing hybridoma cells in a very short time.
Rapid Prime immunization can also be combined with B cell Select or Phage Display.
As part of the careful analysis of the target protein, our scientific experts will recommend suitable animal species and strains for successful completion of your project. Most of our technology-platforms are species-agnostic and can be applied to all animals we offer, including a variety of transgenic animals.
Our genetic immunization protocols have proven successful in the generation of monoclonal antibodies against new, challenging, and conformation-sensitive targets and have been successfully applied in transgenic animals.
Through our proprietary vectors, our algorithm-based protocols produce native protein with appropriate post-translational modifications in vivo and provide very high transfection efficiency. We recommend this technology for complex protein classes, including GPCRs and ion channels as it bypasses the requirement to produce difficult recombinant proteins, and overcomes conformational obstacles of such antigens. Our in-house developed vectors are not subject to downstream milestones and royalties.
The use of transgenic animals producing fully human idiotypes eliminates the need for a humanization step in the race for a human antibody. At ImmunoPrecise we successfully apply the transgenic animal of our client’s choice to our hybridoma, B cell Select® and DeepDisplay™ technologies.
We are proud to have worked with most of the globally available transgenic animal species and strains, making us a preferred CRO for several of them after successful completion of multiple projects for our clients and partners.
Eligible French companies involved with us in research and development may receive a tax credit. Learn More.
Interested in knowing more?
Contact Us